Press realease : BiOkuris signs exclusive agreement with Amdis Health Sciences for UAE Market
December 05, 2024 — Liège, Belgium & Dubai, UAE – BiOkuris, a pioneering biotech company focused on gastrointestinal health, is excited to announce the signing of an exclusive distribution agreement with Amdis Health Sciences for the UAE market. The agreement covers BiOkuris’ flagship product, BK001, an advanced therapeutic solution combining fungal chitin-glucan with simethicone. As part of this partnership, the product will be launched under a private label in the UAE.
BK001’s efficacy is supported by substantial clinical data, recently published in the World Journal of Gastrointestinal Pharmacology and Therapeutics1. The study, demonstrated significant improvements in gastrointestinal symptoms such as bloating and gas in patients with irritable bowel syndrome (IBS). This combination of fungal chitin-glucan and simethicone has been shown to be both effective and well-tolerated in patients, making it an ideal solution for the UAE market.
Amdis Health Sciences, a leader in healthcare solutions in the UAE, will act as the exclusive distributor for BK001 in the region. Their robust regulatory expertise and strong market presence will help ensure the product’s successful launch and sustained growth in the UAE.
François Blondel, CEO and President of the Board at BiOkuris, expressed his enthusiasm for the agreement, stating, “This partnership with Amdis Health Sciences is a major step in BiOkuris’ global strategy, as we expand our reach beyond the EU. BK001 has already shown strong sales performance in Europe, proving its effectiveness and acceptance among patients. The UAE is a key market with a strong demand for innovative healthcare solutions, and we are confident that BK001 will make a significant impact on patients suffering from gastrointestinal disorders.”
The collaboration reflects BiOkuris’ ambition to extend its global footprint, with the UAE serving as a gateway for further international expansion.
Premjith Balakrishnan, CEO of Amdis Health Sciences, added, “We are proud to partner with BiOkuris and bring BK001 to the UAE. This innovative product addresses a critical need to more than 3 million patients in our market seeking effective gastrointestinal therapies, and we expect it to reach the market by Q4 2025. We look forward to introducing it to healthcare professionals and patients throughout the region.”
This agreement will combine Amdis’ market expertise with BiOkuris’ scientific research and innovation, ensuring a successful launch and future collaborations between the two companies.
About BK001
BK001 is a medical device class IIa that is used for:
- The relief of gas-related symptoms such as a bloated feeling, flatulence and abdominal pain
- The regularization of intestinal transit and stool evacuation
- The normalization of the intestinal function
A clinical trial1 demonstrated that four weeks of daily treatment with BK001 is well-tolerated and delivers rapid relief. It effectively reduces abdominal pain, bloating, distension, and flatulence while improving stool consistency and alleviating defecatory disorders.
Each sachet of BK001 contains 500 mg of fungal chitin-glucan combined with 250 mg of simethicone.
About BiOkuris
BiOkuris is a biotech company specializing in innovative solutions for gastrointestinal health. With a strong focus on research and development, the company is dedicated to addressing unmet medical needs through cutting-edge products and therapies. Founded in 2021, BiOkuris has been investing in the development of combination products around the proprietary core technology chitin-glucan (CG) and chitosan. Both are biopolymers derived from the cell walls of Aspergillus niger with a strong potential to transform gastrointestinal healthcare2. For more information about BiOkuris, please visit www.biokuris.com
About Amdis Health Sciences
Amdis Health Sciences is a leading healthcare organization based out of UAE and have operations in wider Middle East and India . Known for its strategic marketing expertise ,strong regulatory expertise coupled with market access strategies and commitment to bringing innovative healthcare solutions to the market, Amdis is a trusted partner for global biotech and pharmaceutical companies. For more information about Amdis Health Sciences, please visit www.amdis.me
For more information
BiOkuris
For media inquiries, please contact: Benoit Palms, Chief Business Officer b.palms@biokuris.com
BiOkuris, Parc Industriel des Hauts Sarts – Zone 2 – 680, rue de Milmorts – 4040 Herstal – Belgium
Amdis Health Sciences
For media inquiries, please contact: info@amdis.me
Amdis Health Sciences Private Limited Rep Office,203, Al Reyami Building, Karama Dubai, U.A.E